Mette D. Hazenberg

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 92 publications

Defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from EBMT Global ComMittee.

Defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from EBMT Global ComMittee.

Journal: Bone marrow transplantation

Published: June 08, 2026

NFкB pathway suppression as a key driver of pacritinib response in high-risk myelofibrosis.

NFкB pathway suppression as a key driver of pacritinib response in high-risk myelofibrosis.

Journal: British journal of haematology

Published: May 12, 2026

Correction: Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.

Correction: Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.

Journal: Bone marrow transplantation

Published: May 05, 2026

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy.

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy.

Journal: Bone marrow transplantation

Published: March 27, 2026

Biovigilance in Faecal Microbiota Transplantation: 7-Year Cohort Study and Framework for Microbiological Assessments of Infectious Adverse Events.

Biovigilance in Faecal Microbiota Transplantation: 7-Year Cohort Study and Framework for Microbiological Assessments of Infectious Adverse Events.

Journal: United European gastroenterology journal

Published: November 10, 2025

Immune reconstitution and infections with ATG versus post-transplant cyclophosphamide as GvHD prophylaxis after nonmyeloablative matched unrelated donor hematopoietic stem cell transplantation.

Immune reconstitution and infections with ATG versus post-transplant cyclophosphamide as GvHD prophylaxis after nonmyeloablative matched unrelated donor hematopoietic stem cell transplantation.

Journal: Frontiers in immunology

Published: November 04, 2025

Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.

Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.

Journal: Bone marrow transplantation

Published: October 20, 2025

Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.

Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.

Journal: Bone marrow transplantation

Published: October 20, 2025

Microbiome, GvHD, and immune reconstitution in allogeneic hematopoietic cell transplantation.

Microbiome, GvHD, and immune reconstitution in allogeneic hematopoietic cell transplantation.

Journal: Bone marrow transplantation

Published: September 16, 2025

An extraction pipeline for analysis of hematopoietic stem cell transplantation data.

An extraction pipeline for analysis of hematopoietic stem cell transplantation data.

Journal: Bone marrow transplantation

Published: May 28, 2025

Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea.

Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea.

Journal: Blood advances

Published: May 23, 2025

Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea.

Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea.

Journal: Blood advances

Published: May 23, 2025

Showing 1-12 of 92

Last Updated: 09/26/2026